Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Welcome and Introduction to Vi3C

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Dec
10
Today In Oncology
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo